CannabisNewsBreaks – Willow Biosciences Inc. (CSE: WLLW) (OTCQB: CANSF) Announces Receipt of Conditional Approval to List on the Toronto Stock Exchange

November 25, 2019 14:18:36

Willow Biosciences Inc. (CSE: WLLW) (OTCQB: CANSF) today announced its receipt of conditional approval from the Toronto Stock Exchange (the “TSX”) to list its common shares on the TSX. According to the update, final approval of the listing is subject to Willow Biosciences meeting certain TSX customary conditions, and Willow will issue a statement upon TSX’s confirmation of the commencement date. “Listing on the TSX is a significant milestone for Willow. The TSX will broaden our investment appeal and leave us well positioned to execute on our strategic initiatives for 2020 and beyond,” Willow President and Chief Executive Officer Trevor Peters said in the news release. “We are excited to add this to our 2019 accomplishments for Willow, which has seen us complete a go-public transaction, raise $37 million in a private placement and subsequent warrant exercise, enter into a potentially game-changing strategic partnership with Noramco, Inc., build out three state-of-the-art laboratories and continue to advance our cannabidiol producing yeast strain towards scale-up expected in the first half of 2020. Willow is uniquely positioned as one of the few public pure-play synthetic biology companies in the world targeting the potentially massive consumer packaged goods and pharmaceutical industries, and being listed on the TSX helps to increase our exposure to global investors.”

To view the full press release, visit

About Willow Biosciences Inc.

Willow is a Canadian biotechnology company based in Calgary, Alberta, that produces high purity, plant-derived compounds that provide building blocks for the global pharmaceutical, health and wellness, and consumer packaged goods industries. Willow’s current focus is in the production of cannabinoids for the treatment for pain, anxiety, obesity, brain disorders, among other significant indications. Willow’s science team has a proven track record of developing manufacturing technologies for high purity compounds in pain and cancer treatments. Willow’s manufacturing process creates a consistent, scalable and sustainable product that allows for the discovery and development of new life changing drugs. For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to WLLW are available in the company’s newsroom at

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published:

Do you have a questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
905.674.5977 Office